Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Oct 17;283(6298):1008–1012. doi: 10.1136/bmj.283.6298.1008

Pathogenesis and treatment of myasthenia gravis.

G K Scadding, C W Havard
PMCID: PMC1507269  PMID: 6794741

Full text

PDF
1008

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almon R. R., Andrew C. G., Appel S. H. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974 Oct 4;186(4158):55–57. doi: 10.1126/science.186.4158.55. [DOI] [PubMed] [Google Scholar]
  2. Bergström K., Franksson C., Matell G., von Reis G. The effect of thoracic duct lymph drainage in myasthenia gravis. Eur Neurol. 1973;9(3):157–167. doi: 10.1159/000114221. [DOI] [PubMed] [Google Scholar]
  3. Berti F., Clementi F., Conti-Tronconi B., Folco G. C. A cholinoceptor antiserum: its pharmacological properties. Br J Pharmacol. 1976 May;57(1):17–22. doi: 10.1111/j.1476-5381.1976.tb07651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bingle J. P., Rutherford J. D., Woodrow P. Continuous subcutaneous neostigmine in the management of severe myasthenia gravis. Br Med J. 1979 Apr 21;1(6170):1050–1050. doi: 10.1136/bmj.1.6170.1050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buckingham J. M., Howard F. M., Jr, Bernatz P. E., Payne W. S., Harrison E. G., Jr, O'Brien P. C., Weiland L. H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976 Oct;184(4):453–458. doi: 10.1097/00000658-197610000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bucknall R. C., Dixon A St J., Glick E. N., Woodland J., Zutshi D. W. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J. 1975 Mar 15;1(5958):600–602. doi: 10.1136/bmj.1.5958.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. CHANG C. C., LEE C. Y. ISOLATION OF NEUROTOXINS FROM THE VENOM OF BUNGARUS MULTICINCTUS AND THEIR MODES OF NEUROMUSCULAR BLOCKING ACTION. Arch Int Pharmacodyn Ther. 1963 Jul 1;144:241–257. [PubMed] [Google Scholar]
  8. Compston D. A., Vincent A., Newsom-Davis J., Batchelor J. R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980 Sep;103(3):579–601. doi: 10.1093/brain/103.3.579. [DOI] [PubMed] [Google Scholar]
  9. Drachman D. B., Angus C. W., Adams R. N., Michelson J. D., Hoffman G. J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978 May 18;298(20):1116–1122. doi: 10.1056/NEJM197805182982004. [DOI] [PubMed] [Google Scholar]
  10. Green D. P., Miledi R., Vincent A. Neuromuscular transmission after immunization against acetylcholine receptors. Proc R Soc Lond B Biol Sci. 1975 Apr 29;189(1094):57–68. doi: 10.1098/rspb.1975.0041. [DOI] [PubMed] [Google Scholar]
  11. Jerne N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 Jan;125C(1-2):373–389. [PubMed] [Google Scholar]
  12. Lindstrom J. M., Seybold M. E., Lennon V. A., Whittingham S., Duane D. D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976 Nov;26(11):1054–1059. doi: 10.1212/wnl.26.11.1054. [DOI] [PubMed] [Google Scholar]
  13. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol. 1977 Jan;7(1):36–43. doi: 10.1016/0090-1229(77)90027-7. [DOI] [PubMed] [Google Scholar]
  14. NASTUK W. L., PLESCIA O. J., OSSERMAN K. E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1960 Oct;105:177–184. doi: 10.3181/00379727-105-26050. [DOI] [PubMed] [Google Scholar]
  15. Newsom-Davis J., Pinching A. J., Vincent A., Wilson S. G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology. 1978 Mar;28(3):266–272. doi: 10.1212/wnl.28.3.266. [DOI] [PubMed] [Google Scholar]
  16. Newsom-Davis J., Wilson S. G., Vincent A., Ward C. D. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979 Mar 3;1(8114):464–468. doi: 10.1016/s0140-6736(79)90823-7. [DOI] [PubMed] [Google Scholar]
  17. Papatestas A. E., Genkins G., Horowitz S. H., Kornfeld P. Thymectomy in myasthenia gravis: pathologic, clinical, and electrophysiologic correlations. Ann N Y Acad Sci. 1976;274:555–573. doi: 10.1111/j.1749-6632.1976.tb47715.x. [DOI] [PubMed] [Google Scholar]
  18. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973 May 25;180(4088):871–872. doi: 10.1126/science.180.4088.871. [DOI] [PubMed] [Google Scholar]
  19. Pinching A. J., Peters D. K. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976 Dec 25;2(8000):1373–1376. doi: 10.1016/s0140-6736(76)91917-6. [DOI] [PubMed] [Google Scholar]
  20. Scadding G. K., Thomas H. C., Havard C. W. The immunological effects of thymectomy in myasthenia gravis. Clin Exp Immunol. 1979 May;36(2):205–213. [PMC free article] [PubMed] [Google Scholar]
  21. Scadding G. K., Webster A. D., Ross M., Thomas H. C., Havard C. W. Humoral immunity before and after thymectomy in myasthenia gravis. Neurology. 1979 Apr;29(4):502–506. doi: 10.1212/wnl.29.4.502. [DOI] [PubMed] [Google Scholar]
  22. Shibuya N., Mori K., Nakazawa Y. Serum factor blocks neuromuscular transmission in myasthenia gravis: electrophysiologic study with intracellular microelectrodes. Neurology. 1978 Aug;28(8):804–811. doi: 10.1212/wnl.28.8.804. [DOI] [PubMed] [Google Scholar]
  23. Symington G. R., Mackay I. R., Lambert R. P. Cancer and teratogenesis: infrequent occurrence after medical use of immunosuppressive drugs. Aust N Z J Med. 1977 Aug;7(4):368–372. doi: 10.1111/j.1445-5994.1977.tb04397.x. [DOI] [PubMed] [Google Scholar]
  24. Takamori M., Iwanaga S. Experimental myasthenia due to alpha-bungarotoxin. Neurology. 1976 Sep;26(9):844–848. doi: 10.1212/wnl.26.9.844. [DOI] [PubMed] [Google Scholar]
  25. Toyka K. V., Brachman D. B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975 Oct 24;190(4212):397–399. doi: 10.1126/science.1179220. [DOI] [PubMed] [Google Scholar]
  26. Toyka K. V., Drachman D. B., Griffin D. E., Pestronk A., Winkelstein J. A., Fishbeck K. H., Kao I. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977 Jan 20;296(3):125–131. doi: 10.1056/NEJM197701202960301. [DOI] [PubMed] [Google Scholar]
  27. Vincent A., Newsom-Davis J., Martin V. Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis. Lancet. 1978 Jun 10;1(8076):1254–1254. doi: 10.1016/s0140-6736(78)92481-9. [DOI] [PubMed] [Google Scholar]
  28. Vincent A., Newsom-Davis J., Martin V. Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis. Lancet. 1978 Jun 10;1(8076):1254–1254. doi: 10.1016/s0140-6736(78)92481-9. [DOI] [PubMed] [Google Scholar]
  29. Wekerle H., Ketelsen U. P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet. 1977 Mar 26;1(8013):678–680. doi: 10.1016/s0140-6736(77)92118-3. [DOI] [PubMed] [Google Scholar]
  30. White M. C., De Silva P., Havard C. W. Plasma pyridostigmine levels in myasthenia gravis. Neurology. 1981 Feb;31(2):145–150. doi: 10.1212/wnl.31.2.145. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES